How did ECOR's revenue trends evolve in Q4 2024?

ECOR's revenue trends in Q4 2024 showed robust growth, reflecting strategic expansions and strong market demand for their bioelectronic medicine portfolio. 1. **Revenue Growth**: ECOR reported a revenue of $25 million for the year 2024, with a significant surge in Q4, reaching $7 million. This represents a 35.7% increase from the same quarter in the previous year. 2. **Gross Margins**: The company maintained strong gross margins of 85-86% over the past 8-9 quarters, indicating efficient cost management and a profitable operating model. 3. **New Product Contributions**: The acquisition of Quell technology for fibromyalgia and distribution agreements for Relatex and Sparrow contributed to revenue growth. These products are expected to expand ECOR's market reach and customer base. 4. **Market Potential**: ECOR's non-invasive vagus nerve stimulator, gammaCore, has FDA approval for six conditions, with cluster headaches and migraines being the most significant. The device is sold on prescription, generating recurring revenue. 5. **Financial Outlook**: ECOR aims to achieve cash positivity in 2025, supported by strategic expansions and a focus on increasing payer coverage. The company's financial performance and growth prospects are positive, supported by strong revenue growth and strategic initiatives. In conclusion, ECOR's revenue trends in Q4 2024 were marked by strong growth, driven by new product contributions, strategic acquisitions, and effective cost management. The company's focus on expanding its bioelectronic medicine portfolio and optimizing its operations positions it well for future financial success.